Topic: The Medicines Company
Tweet Print | Email | abilitation Institute's new hospital to have 50% more beds Baxter suing insurer to recoup millions in bad blood settlements...
January 23, 2012 07:30 AM Eastern Time . SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today...
Shares of Ligand Pharmaceuticals (LGND) have continued to climb since we first reported in August that insider buying in the stock was on the...
Things are looking up for The Medicines Company (MDCO) (from here, "TMC") once more. Shares in the New Jersey group gained 17% last week to $17.37...
Posted on 10/04/11 at 11:59am by Investor Ideas . POINT ROBERTS - October 4, 2011 - www.InvestorIdeas. com, a global investor research portal for...
IntriCon (NasdaqGM: IIN) soared 35% Monday on news that it had been chosen to be the original equipment manufacturer (OEM) of hearing aids for hi...
Equities research analysts at Argus lowered their price target on shares of The Medicines Compan (NASDAQ: MDCO) from $25.00 to $20.00 in a research...
Equities research analysts at Argus upgraded shares of The Medicines Compan (NASDAQ: MDCO) from a "hold" rating to a "buy" rating in a research...
Several readers had the same complaint with my story Monday on how biotechnology executives are heartened by the beginnings of a sense of clarity from the Food and Drug Administration: Chief executive Nick Landekic talked a good game in an interview, but ...
"The HORIZONS-AMI trial demonstrates a commitment by The Medicines Company to continued innovation with Angiomax," said Clive Meanwell, President and Chief Executive Officer of The Medicines Company. HORIZONS-AMI, co-funded by a grant from The Medicines Company, is the largest study to focus ...